Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31432650 | 1.00 | LTB4R2 (1.00) | LTB4R2AGTR1 | |
| SCHEMBL17158389 | 0.91 | LTB4R2 (0.83) | LTB4R2AGTR1 | |
| SCHEMBL14691607 | 0.90 | LTB4R2 (1.00) | LTB4R2AGTR1 | |
| SCHEMBL17158349 | 0.89 | LTB4R2 (1.00) | LTB4R2AGTR1 | |
| SCHEMBL14706246 | 0.86 | LTB4R2 (0.87) | LTB4R2AGTR1 | |
| SCHEMBL3124962 | 0.85 | LTB4R2 (1.00) | LTB4R2AGTR1 | |
| SCHEMBL17158351 | 0.85 | LTB4R2 (0.74) | LTB4R2AGTR1 | |
| SCHEMBL14691538 | 0.84 | LTB4R2 (0.79) | LTB4R2AGTR1 | |
| SCHEMBL17158350 | 0.84 | LTB4R2 (0.74) | LTB4R2AGTR1 | |
| SCHEMBL14691637 | 0.84 | LTB4R2 (1.00) | LTB4R2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215146-B1 | BLT2 AGONISTS FOR THE TREATMENT OF PAIN | FRAUNHOFER GES FORSCHUNG (DE) | 2021-02-17 | — | — | EP | claimed |
| US-20150291509-A1 | NOVEL BIPHENYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING THE SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-10-15 | — | — | US | claimed |
| US-8673889-B2 | BLT2-mediated disease, BLT2 binding agent and the compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-18 | — | — | US | claimed |
| WO-2013022243-A2 | NOVEL BIPHENYL DERIVATIVE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING SAME AS AN ACTIVE INGREDIENT | 동국대학교 산학협력단 (KR) | 2013-02-14 | — | — | WO | claimed |
| EP-2172222-A2 | Novel BLT2-mediated disease, BLT2-binding agent and compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-04-07 | — | — | EP | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250268870-A1 | SMALL MOLECULE INDUCERS OF CARDIOMYOCYTES TO IMPROVE CARDIAC STRUCTURE AND FUNCTION | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-08-28 | — | — | US | disclosed |
| WO-2025088073-A1 | HETEROCYCLIC COMPOUNDS AS BLT2 AGONISTS AND THEIR MEDICAL USE | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2025-05-01 | — | — | WO | disclosed |
| EP-4545138-A1 | HETEROCYCLIC COMPOUNDS AS BLT2 AGONISTS AND THEIR MEDICAL USE | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2023205099-A2 | SMALL MOLECULE INDUCERS OF CARDIOMYOCYTES TO IMPROVE CARDIAC STRUCTURE AND FUNCTION | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3327001-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2022-04-13 | — | — | EP | disclosed |
| WO-2013022243-A2 | NOVEL BIPHENYL DERIVATIVE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING SAME AS AN ACTIVE INGREDIENT | 동국대학교 산학협력단 (KR) | 2013-02-14 | — | — | WO | disclosed |
| EP-2172222-A2 | Novel BLT2-mediated disease, BLT2-binding agent and compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172222-A2 | Novel BLT2-mediated disease, BLT2-binding agent and compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1745800-A1 | NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745800-A1 | NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268870-A1 | SMALL MOLECULE INDUCERS OF CARDIOMYOCYTES TO IMPROVE CARDIAC STRUCTURE AND FUNCTION | CKMT1A; CKMT1B, TFAM, TFB2M | LTB4R2 4877/4885AGTR1 4490/4885 |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | MALT1, SLC10A2, LCP2 | LTB4R2 66/4885AGTR1 996/4885 |
| US-20150291509-A1 | NOVEL BIPHENYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING THE SAME AS ACTIVE INGREDIENT | CD47, MSR1, CD14 | LTB4R2 681/4885AGTR1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.